Literature DB >> 561913

Assessment of muscle strength in Duchenne muscular dystrophy.

F A Ziter, K G Allsop, F H Tyler.   

Abstract

Muscle strength in 23 patients with Duchenne dystrophy was tested against gravity and manual resistance during an 8-year period. The data show striking linearity in rate of loss of strength with age for any given patient. The tempo does not appear altered during growth spurts, bracing, or loss of ambulation. Variability in disease severity was documented clearly by 7 years of age and appears to be related to earlier age at onset of symptoms. This long ignored method of muscle strength assessment provides a precise measure of disease progression and, since the technique is widely used by physical therapists, it should be incorporated in clinical studies and therapeutic trials.

Entities:  

Mesh:

Year:  1977        PMID: 561913     DOI: 10.1212/wnl.27.10.981

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

2.  Electrical impedance in the lower limbs of patients with Duchenne muscular dystrophy: a preliminary study.

Authors:  M Noshiro; T Morimoto; H Nagao; H Matsuda
Journal:  Med Biol Eng Comput       Date:  1993-03       Impact factor: 2.602

3.  The measurement of muscle strength in patients with peripheral neuromuscular disorders.

Authors:  C M Wiles; Y Karni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-11       Impact factor: 10.154

4.  Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.

Authors:  Emma Ciafaloni; Anil Kumar; Ke Liu; Shree Pandya; Christina Westfield; Deborah J Fox; Kristin M Caspers Conway; Christopher Cunniff; Katherine Mathews; Nancy West; Paul A Romitti; Michael P McDermott
Journal:  J Pediatr Rehabil Med       Date:  2016

Review 5.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

6.  Duchenne muscular dystrophy quantification: a multivariate analysis of surface EMG.

Authors:  A Priez; J Duchene; F Goubel
Journal:  Med Biol Eng Comput       Date:  1992-05       Impact factor: 2.602

Review 7.  Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy.

Authors:  Emma Rybalka; Cara A Timpani; Christos G Stathis; Alan Hayes; Matthew B Cooke
Journal:  Nutrients       Date:  2015-11-26       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.